Halozyme Therapeutics, Inc. (HALO)
67.37
+0.01
(+0.01%)
USD |
NASDAQ |
Mar 06, 16:00
67.98
+0.61
(+0.91%)
After-Hours: 20:00
Halozyme Therapeutics Free Cash Flow : 644.59M for Dec. 31, 2025
Free Cash Flow Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Johnson & Johnson | 19.70B |
| Skye Bioscience, Inc. | -41.53M |
| AIM ImmunoTech, Inc. | -13.33M |
| Stryker Corp. | 4.283B |
| Glaukos Corp. | -39.06M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | 219.03M |
| Cash from Investing (Quarterly) | -741.79M |
| Cash from Financing (Quarterly) | 239.52M |
| Free Cash Flow Per Share (Quarterly) | 1.849 |
| Free Cash Flow to Equity (Quarterly) | -448.84M |
| Free Cash Flow to Firm (Quarterly) | 224.50M |
| Free Cash Flow Yield | 7.80% |